Citius Pharmaceuticals: From Development Stage to Commercial Oncology – A Live Discussion with CEO Leonard Mazur
Wednesday, March 11, 2026
11:00 AM – 12:00 PM ET
Citius Pharmaceuticals has officially crossed a major threshold.
After years as a development-stage biotech, the company has reported its first commercial revenue, following the U.S. launch of LYMPHIR, generating $3.9M in fiscal Q1 sales, in what can be viewed as a strategic inflection point.
Now the key question becomes: How does Citius scale from its initial oncology launch to deliver meaningful revenue visibility in 2026, and beyond?
Review this live webinar recording with Jason Kolbert, Head of Research at D. Boral Capital and Leonard Mazur, Chairman and Chief Executive Officer of Citius Pharmaceuticals, who discuss:
- Early LYMPHIR launch traction and physician adoption
- Commercial execution strategy in a rare oncology market
- Balance sheet positioning, including recent $3.8M non-dilutive funding
- Revenue ramp expectations into 2026 and 2027
- The role of Mino-Lok and Halo-Lido in portfolio diversification
- Strategic priorities as Citius transitions into a multi-asset commercial company
Citius is no longer just a pipeline story. It is now executing on its objectives as a commercial-stage oncology company with multiple late-stage assets.
If you follow emerging oncology platforms or commercial-stage biotech transitions, this fireside conversation is one you will want to watch.
Jason Kolbert
Head of Research
D. Boral Capital











